Regeneron convinces PTAB to review Novartis syringe patent
28-10-2021
Regeneron asks court to dismiss COVID-19 tech patent suit
24-08-2021
The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Regeneron Pharmaceuticals, Eylea, PTAB, Mylan Pharmaceuticals, Novartis
